Browse the Biomedical Sciences Collections
Effects of Early Life Neglect on Adolescent Cocaine Use and Expression of Fibroblast Growth Factor-2 in the Brain
Early-life adversity (ELA) increases the risk for development of psychopathologies in adolescence and adulthood. Childhood neglect is a potent form of ELA and can be modeled through neonatal maternal separation. Maternal separation has been shown to alter cognition, learning and memory later in life. Here, we examined the contribution of maternal separation to the development of substance use disorder in adolescence, and whether changes in regional protein expression in the brain persist into adulthood. First, male and female rats exposed to maternal separation were compared to controls for changes in localized expression of the developmental growth factor, fibroblast growth factor-2 (FGF2), in several brain regions using immunohistochemistry. FGF2 is known to be upregulated by cocaine experience, is protective against fear over-expression and is a candidate biomarker for vulnerability and resilience to development of comorbid psychopathologies. Next, we examined whether maternal separation impacted sensitivity in adolescence to cocaine using the conditioned place preference paradigm, in which one of two chambers is associated with cocaine. Finally, we determined whether maternal separation altered regional FGF2 expression in the brain during adulthood, and if cocaine experience in adolescence had an impact. We are currently processing the brain tissue to examine regional FGF2 expression and have completed the conditioned place preference protocol. Our results will determine whether FGF2 is a potential risk or resilience factor for the development of psychopathologies and will pave the way for future studies examining comorbid addiction and fear disorders.Mitochondrial Dynamics in Neurodegenerative Mouse Models
Neurodegenerative diseases are becoming more common in today’s world. Two of the more prominent diseases that fall into this category are multiple sclerosis (MS) and Alzheimer’s disease (AD). A hallmark for both of these diseases is mitochondrial dysfunction. Mitochondrial dysfunction causes an increase in the number of damaged mitochondria, which is linked to a decrease in the energy supply for the cell. Mitophagy is a mechanism known for eliminating damaged mitochondria and is impaired in neurodegenerative diseases. This causes an accumulation of damaged mitochondria in the cell leading to loss of function. We have also shown that a dietary factor known as betaine, is able to restore energy production within the dysfunctional mitochondria. In the present study, we are investigating the role of betaine in both AD and cuprizone mouse models, hypothesizing that betaine will restore energy production by eliminating damaged mitochondria using mitophagy.The Role of the Locus Coeruleus on Regulating Sickness-like Behaviors
Elevated peripheral cytokines result in sickness and depression-like behaviors by signaling through the vagus nerve. Stimulation of the vagus nerve activates noradrenergic neurons in the nucleus of the solitary tract (NTS) and release of norepinephrine (NE) at projection sites that regulate behavior. Previous studies indicate that neurons in the locus coeruleus (LC) inhibit neurons in the NTS. This led to the hypothesis that LC neurons may act as a brake to inhibit sickness behaviors. To test this hypothesis, rats underwent baseline behavioral testing before being injected with either saline or DSP4, a neurotoxin that lesions LC neurons. Three weeks later animals underwent further behavioral testing before all animals received live E.coli injections and sickness behaviors were recorded. We expected lesioning the LC would result in greater sickness behaviors following E.coli by removing the inhibitory regulation of NTS projection neurons; however, lesioned animals had similar body weights, food intake, and sucrose intake compared to controls following E.coli challenge. Interestingly, DSP4 treated rats showed greater anxiety-like behaviors in an open field test three weeks following DPS4 and less sickness behaviors in an open field following E.coli compared to controls. The results did not support our initial hypothesis, but do support a role for LC neurons in regulating sickness and/or depression/anxiety-like behaviors. Future studies will look more into the role the LC plays in regulating behaviors and the interactions between NTS, LC, and prefrontal cortex (an area important for emotional and motivated behaviors).
Bryan Soth Abstracts for Research Symposium - RACK1 Rescue Project
Down syndrome occurs due to triplication of human chromosome 21, and results in many phenotypic defects including slow wound healing, intellectual disability and reduced muscle tone. Here we focus on the role of adhesions in this disorder, which are involved in tissue development, cell migration, and memory formation. Previous work from our lab demonstrates that fibroblasts from individuals with Down syndrome have increased focal adhesions, which are multi-protein complexes that link the extracellular matrix to the intracellular cytoskeleton. We also found that the area, perimeter and motility of Down syndrome fibroblasts is altered. Taken together, these data suggest that increased adhesion may lead to reduced cellular motility in Down syndrome. Here we show that RACK1, a scaffolding protein and member of the focal adhesion complex, is overexpressed in Down syndrome fibroblasts. We also demonstrate that RACK1 can be knocked down with shRNA in Down syndrome fibroblasts to levels comparable to apparently healthy control cells. We are currently investigating whether knocking down RACK1 to control values is able to rescue the phenotypic defects present in Down syndrome fibroblasts, such as cell size, cell shape, and motility. Furthermore, substrate type is known to have a profound effect on protein expression and differentiation, and we have preliminary data that the substrate affects the expression level of RACK1 differentially in Down syndrome fibroblasts. Examining the role of RACK1 in Down syndrome is relevant for understanding the phenotypic defects of individuals with this disorder and may also provide insight into therapeutic and clinical treatments.Identification of Opioid Receptors in Mixed Cortical Cultures
Introduction: The six layers of the rat cerebral cortex consists of around twenty-one million cells which can be sub-divided into distinct neuronal and glial populations (e.g. GABAnergic, Glutaminergic, Astrocytic). These neuronal populations are differentially targeted by both licit and illicit drugs to alter cellular states, excitability, and/or behavioral outcome. Opioids alter cortical excitability through inhibition of GABAnergic inhibitory interneurons leading to disinhibition of glutaminergic neurons and downstream excitation of dopaminergic neurons. Resulting in altered reward evaluation and opioid induce analgesia. Objective: To use Immunocytochemistry - Immunofluorescence to identify the key cellular targets of opioids in the cortex. Methods: Cortical neurons were isolated from (P0) rat pups, cultured on glass coverslips and allowed to form mature synapses over 12 days. On days 13-20 cultures were Immuno-labeled with neuronal (Anti-NeuN), Astrocytic (Anti-GFAP), GABAnergic (Anti-GAD67) and Mu1 Opioid receptor (Anti-OPRM1) conjugated antibodies and imaged at 405nm, 488nm, 550nm, and 633nm respectively on an inverted confocal microscope. Results: Opioid receptors were found to be co-localized with GAD67 and NeuN labeling with little to no detectable expression on astrocytes or other neuronal subpopulations. Conclusion: These data support previous evidence that opioids selectively act on specific subpopulations of cortical neurons that suppress and limit cortical excitability.Methods to Create a Multi Modal Imaging Probe
Magnetic resonance imaging (MRI) scans use a combination of radio waves and magnetic fields to create an image of tissues within the body. While MRI is proven effective it only has limited use as to which tissue structures can be accurately resolved. Using contrast agents in MRI, it is possible to gain enhanced detail in acquired images to help resolve disease symptoms, tissue activity, and improve the signal of tissues during a scan. Contrast agents are used in patients with Multiple Sclerosis to detect lesions in brain tissue. Two issues with current contrast agents is their lack of specificity and toxicity at relatively low doses. Recently, a new a gadolinium-based nanoparticle (GdNP) has been developed. GdNP is approximately ten times stronger than typical contrast agents allowing it to provide the same contrast enhancement with ten percent of the typically required concentration. Targeting agents further decrease the number of molecules needed for desired image enhancement by binding to specific areas of the tissues being studied. This research is based around developing and evaluating nanoparticle-targeting agents as contrast enhancing probes with tissue specificity. The albumin binding protein, Evans blue (EB), have been attached to contrast enhancing nanoparticles. EB targets serum albumin (SA) in the blood vessels when injected intraperitoneally. We present in vivo MRI and microscopic data detailing development and usage of this new probe designed to enhance signal from the neurovasculature of a mouse brain.